文献速递消化道肿瘤放疗放疗物理与技术姑息放疗与转移瘤

骨盆恶性肿瘤再程放疗:超分割加速质子再照射

Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies.
PubMed 文献 · Clin Transl Radiat Oncol · 2019-08-27

质子计划较光子计划显著降低骨盆骨髓平均剂量及低剂量照射体积。中位随访13.9个月,1年总生存率67.5%,1年无进展生存率58.7%,未发生4级急性或晚期毒性。

要点

  • 质子再照射较光子计划显著降低骨盆骨髓平均剂量及V5、V10、V20、V30。
  • 超分割加速质子再照射耐受良好,未观察到4级急性或晚期毒性。
  • 根治性再照射未联合手术时局部控制率有限,建议多学科协作。

核心结论

  • 质子束再照射较光子再照射能更好地保护骨盆骨髓,临床耐受性良好。
  • 但根治性再照射未后续手术切除时控制率有限,应优先多学科综合治疗。

研究设计与样本

  • 再照射为每日两次、间隔至少6小时、每次1.5 Gy(RBE),总剂量39-45 Gy(RBE),全部同步化疗。
  • 生成对应光子计划进行配对剂量学比较,采用Wilcoxon符号秩检验,生存分析采用Kaplan-Meier法。

主要发现

  • 质子再照射计划较光子计划骨盆骨髓平均剂量更低,骨盆骨髓V5、V10、V20、V30均更低(p<0.001、p<0.001、p<0.001、p=0.033)。
  • 中位随访13.9个月,5例出现局部复发,4例出现远处转移。
  • 质子再照射后1年总生存率为67.5%,1年无进展生存率为58.7%。
  • 未发生急性或晚期4级毒性。

关键数值与推荐

  • 再照射总剂量39-45 Gy(RBE),每次1.5 Gy(RBE),每日两次,间隔至少6小时。
  • 既往骨盆放疗中位剂量50.4 Gy(范围25-80 Gy),距再照射中位时间4.7年(范围1.0-36.1年)。

临床怎么用

  • 对既往接受过骨盆放疗的直肠或肛管癌患者,可考虑超分割加速质子再照射以保护骨盆骨髓。
  • 根治性再照射未联合手术时局部控制有限,应多学科评估手术等综合治疗策略。

局限性

  • 剂量学比较采用生成的光子计划,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pelvic reirradiation (re-RT) presents challenges due to concerns for late toxicity to tissues-at-risk including pelvic bone marrow (PBM). We routinely utilize a hyperfractionated, accelerated re-RT for recurrent rectal or anal cancer in the setting of prior radiation. We hypothesized that proton beam radiation (PBR) is uniquely suited to limit doses to pelvic non-target tissues better than photon-based approaches. MATERIALS AND METHODS: All patients who received hyperfractionated, accelerated PBR re-RT to the pelvis from 2007 to 2017 were identified. Re-RT was delivered twice daily with a 6 h minimum interfraction interval at 1.5 Gray Relative Biological Effectiveness (Gy(RBE)) per fraction to a total dose of 39-45 Gy(RBE). Concurrent chemotherapy was given to all patients. Comparison photon plans were generated for dosimetric analysis. Dosimetric parameters compared using a matched-pair analysis and the Wilcoxon signed-rank test. Survival analysis was performed Kaplan Meier curves. RESULTS: Fifteen patients were identified, with a median prior pelvic RT dose of 50.4 Gy (range 25-80 Gy). Median time between the initial RT and PBRT re-RT was 4.7 years (range 1.0-36.1 years). In comparison to corresponding photon re-RT plans, PBR re-RT plans had lower mean PBM dose, and lower volume of PBM getting 5 Gy, 10 Gy, 20 Gy, and 30 Gy (p < 0.001, p < 0.001, p < 0.001, and p = 0.033, respectively).With median 13.9 months follow-up after PBR re-RT, five patients had developed local recurrences, and four patients had developed distant metastases. One-year overall survival following PBR re-RT was 67.5% and one-year progression free survival was 58.7%. No patients developed acute or late Grade 4 toxicity. CONCLUSION: PBR re-RT affords improved sparing of PBM compared with photon-based re-RT. Clinically, PBR re-RT is well-tolerated. However, given modest control rates with definitive re-RT without subsequent surgical resection, a multidisciplinary approach should be favored in this setting when feasible.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Moningi S, Ludmir EB, Polamraju P, et al. Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol. 2019. PMID: 31517071. doi:10.1016/j.ctro.2019.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。